WHO Sounds Alert Over Acute Lack of Weight-Loss Jabs

Less than a tenth of patients that would benefit from obesity jabs including Wegovy can access them, warns the global health agency as it issues its first recommendations on the therapies.

Given in excess of 1,000,000,000 people worldwide currently obese, it is urging more widespread and fairer access to these injectable treatments.

Based on estimates, over two billion are projected to be obese by 2030 if no action is taken.

"The new guidance acknowledges that excess weight is a long-term condition that can be managed with holistic and continuous treatment," said the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and supply-chain constraints are key barriers to widespread availability to the jabs that can help people shift significant weight, says the organization.

Skinny Jab Scarcity

Despite the present most optimistic case, the production of these medications would only suffice for approximately 100 million people – under 10% of those who need them, according to the WHO.

The guideline encourages nations and manufacturers to expand access, through measures like licensing agreements.

A patent on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.

How Weight-Loss Drugs Function

GLP-1 drugs replicate a biological compound to reduce digestion speed, curb appetite and enhance the sense of being full so users eat less.

People usually see weight reduction after several weeks of starting on the weekly injections.

Research points to users may put most of the weight back on within a year of halting the medication, as their normal appetite come back.

Being carrying excess weight increases your likelihood for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.

Excess weight affects individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the WHO.